




A Discussion of A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD)

Hosted by Christopher C Cheung, MD, MPH, FHRS

Today's Host



Christopher C Cheung, MD, MPH, FHRP
Sunnybrook HSC, University of Toronto



Today's Contributors:



**Edward P. Gerstenfeld,
MD, MS, FHRS
University of California,
San Francisco**



**Paul C. Zei, MD, PhD,
FHRS
Mass General Brigham**



Disclosures:

Christopher C Cheung, MD, MPH, FHRS

- **Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biotronik, Biosense Webster, Inc., Abbott**

Edward P. Gerstenfeld, MD, MS, FHRS

- **Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Abbott, Boston Scientific, Varian Medical Systems**
- **Other Non-Financial Relationships: Adagio Medical, Boston Scientific, Abbott Medical**
- **Research: Abbott Medical**
- **Officer, Trustee, Director, Committee Chair, or Other Fiduciary Role: American College of Cardiology**

Paul C Zei, MD, PhD, FHRS

- **Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Varian Medical Systems, Biosense Webster, Inc., Abbott, Boston Scientific, APT Medical**
- **Research: Biosense Webster, Inc.**





Thank you!